AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Pr...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Pr...
Source route
Continue on amgen.com
Leave the platform to read the original full article on the publisher site.
Source: Amgen (Global News)
Scope: Industry
Related coverage
More related coverage
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
Pharmacists at Orion – The many paths a pharmacy degree can open up in the pharmaceutical industry4/7/2026 We are Orion Pharma
Pharmacy-trained professionals are in high demand across the pharmaceutical industry – from supply c...